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the application of this highly effective cancer treatment. As a localized intervention,
the dependence on sensitive, specific, and accurate imaging to define the extent of dis-
ease, its heterogeneity, and adjacency to normal tissues directly affects the therapeutic
ratio. Image-based in vivo temporal monitoring of the response to treatment enables
adaptation and further affects the therapeutic ratio. Thus, more precise intervention will
enable fractionation schedules that better interoperate with advances such as immuno-
therapy. In the data seterich era that promises precision and personalized medicine,
the radiation oncology field will integrate these new data into highly protocoled path-
ways of care that begin with multimodality prediction and enable patient-specific adap-
tation of therapy based on quantitative measures of the individual’s doseevolume
temporal trajectory andmidtherapy predictions of response. In addition to advancements
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Volume 101  Number 2  2018 Imaging advances and precision radiation oncology 293of pre- and peritherapeutic markers derived from advances in molecular pathology (eg,
tumor genomics), automated and comprehensive imaging analytics (eg, radiomics, tu-
mor microenvironment), and many other emerging biomarkers (eg, circulating tumor
cell assays) will need to be integrated to maximize the benefit of radiation therapy for
an individual patient. We present a perspective on the promise and challenges of fully
exploiting imaging data in the pursuit of personalized radiation therapy, drawing from
the presentations and broader discussions at the 2016 American Society of Therapeutic
Radiation OncologyeNational Cancer Institute workshop on Precision Medicine in Ra-
diation Oncology (Bethesda, MD).  2018 Published by Elsevier Inc.Introduction
The advent of computed tomography (CT), magnetic reso-
nance (MR) imaging, and positron emission tomography
(PET) in the past 50 years has transformed the detection and
treatment of cancer. These technologies have had a pro-
found impact on our ability to better predict the outcomes of
existing interventions and enabled a period of remarkable
innovation, bringing new interventions and paradigms of
care. The continued pace of advancement in imaging tech-
nology, combined with our growing ability to analyze the
data from individual patients and aggregate these data
across large patient cohorts, is creating a future in which
care is becoming increasingly precise and personalized.
Thus, the intervention is optimized according to well-
defined patient-specific measurement regimens (eg, imag-
ing, genomics, epigenomics) that have been derived from
aggregated learning through large cohort data sets. The
minimally invasive nature of imaging portrays its unique
and critical role as an enabler of precision medicine in
radiation oncologydwhether that precision is in better
defining the patient-specific extent of disease or being used
in combination with many other inputs to design the time-
dependent pattern of dose to be applied.
Although imaging has always played a central role in
radiation oncologydas evidenced by most radiation
oncology departments starting as divisions within the
radiology departmentdimaging and image-derived sig-
nals will be even more integral to future practice. Image-
derived features (eg, tumor size, location, imaging
phenotype, texture) are now affecting nearly every facet
of patient care and are used at every step (eg, diagnosis,
daily treatment delivery, response assessment) in the
process. Figure 1 illustrates the many image-related ac-
tivities in the processes of patient characterization, de-
cision making, care delivery, and follow-up phases of a
patient’s journey through modern radiation therapy.
Isolating the effect of advances in imaging is chal-
lenging, given the wide diversity of roles it plays.
Furthermore, advances in 1 domain can enhance or
diminish the importance of imaging in another. The
development of MR-guided radiation therapy systems is
an example in which consolidation of a diagnostic MR
scanner with a linear accelerator might enable integrated
delineation, adaptation, and response assessment from asingle system (ie, daily MR imaging of the patient during
treatment) (1). The schematic in Figure 1 also highlights
2 other important conceptsdintent and information flow.
With the emergence of rich new information during the
course of therapy, the clinician must focus on clinical
intent instead of “prescription.” Although previously
considered “tampering” with evidence-based practice,
the idea of adaptation within the course of therapy be-
comes a potential reality with the emergence of robust,
noninvasive imaging signals, including anatomic and
functional changes (2, 3). The field of radiation oncology
has been a “first mover” in this area, with the develop-
ment of adaptive radiation therapy enabled by image-
guidance systems (4, 5). The effective and efficient
flow of information (Fig. 1) is central to enabling this
paradigm. Robust data exchange standards, gigabit data
transfer speeds, on-demand computing capacity, artificial
intelligence-based automation methods, and deformation
technologies are enablers, and their scale up in the era of
“big data” will open the door for greater consumption of
imaging data in the field of radiation oncology (6). The
success of the precision medicine paradigm requires that
these diverse imaging data be drawn together with
genomic data (including epigenetics), phenotypic data
(eg, tumor microenvironment), emerging models of ra-
diation biology (eg, radiogenomics, immunotherapy),
and, of utmost importance, clinical outcomes.
In June 2016, the American Society of Radiation
Oncology, National Cancer Institute, and American Asso-
ciation of Physicists in Medicine co-sponsored a 2-day
workshop for radiation oncology physicians and medical
physicists focused on precision medicine in radiation
oncology. The workshop provided leaders the opportunity
to interact with their peers and identify a new foundation of
conducting research to bring the precision medicine para-
digm to radiation oncology. Specific insights were sought
regarding the future scientific direction of radiation
oncology, the digital infrastructure needed to participate,
and the practical and logistical barriers to enabling preci-
sion medicine in radiation oncology. Presentations and
dialogue concentrated on genomics, imaging, big data, and
real-world challenges to advance precision medicine in
radiation oncology research, quality assurance, and safety.
In addition to scientific posters and oral presentations from
experts in the field, a dedicated workshop session for each
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Fig. 1. Multiple roles of imaging in the multiple timescales of personalizing radiation therapy. The practice of radiation
oncology uses imaging data at every point in the process, including characterization of the patient and his or her disease, prediction
of the outcome, design of the dose distribution, targeting and adaptation, real-time tracking, and response assessment. Image-based
information informs the intent and enables patient-specific personalization of the treatment. In the absence of precision, this
process will not build evidence nor increase our understanding of the disease or the effectiveness of our interventions. Pursuing the
precision medicine paradigm requires us to improve our models of response and automate the flow of information.
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and future directions to advance the precision cancer
medicine paradigm. The key imaging themes presented and
workshop outcomes are presented in this report.Rapid Pace of Advances in
ImagingdMeasurement Is King
Molecular imaging approaches have long held the promise
of augmenting the anatomic approach currently used for
the design of highly conformal radiation dose distributions
(7). The science of radiobiology, augmented by the ability
of molecular imaging to assess the spatial heterogeneity of
tumors, provided the basis for this approach, with decades
of evidence highlighting the variation in the radiosensi-
tivity of cells depending on the type, location in the cell
cycle, and microenvironment (8). Without the ability to
localize phenotypic heterogeneity, the entire tumor must
be dosed to some minimum dose to ensure the most
resistant disease is controlled. The effect of this approach
on the adjacent normal tissues and the subsequent deter-
mination of patient-specific tolerance to a course of ra-
diation therapy severely limited the development of more
personalized radiation therapy regimens.For the purposes of our report, focusing on the topic of
hypoxia will be illustrative. The effect of very low oxygen
levels on cell radiosensitivity has been established in basic
science and is a well-documented negative predictive factor
in the outcomes of a variety of cancers, including cancer of
the cervix, head and neck, and prostate (9-12). Although
most of these studies were performed using an invasive
oxygen sensing Eppendorf probe, others have used PET
imaging approaches to determine the magnitude and dis-
tribution of hypoxia in the tumor (13). In addition to giving
valuable input into patient cohort classification, these re-
sults also highlight the potential to design hypoxia-
escalating and normoxia de-escalating dose distributions
(14, 15). Implicit in this approach is the assumption that
these molecular patterns are accurate representations of the
underlying biology and are stable throughout the course of
radiation therapy (16, 17) (Fig. 2).
These exciting advances in molecular imaging of
hypoxia raise many questions and define key areas of
research for the inclusion of molecular imaging into the
field of radiation oncology. Do we have the spatial reso-
lution in our application of dose that is consistent with the
imaging findings, and does the imaging modality have the
ability to spatially resolve the underlying biology? (18).
Do we consider these signals as absolute quantities, or do
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Fig. 2. Preclinical research in multimodality molecular imaging emphasizes the complex response of the disease before,
during, and after radiation therapy (17). Using fludeoxyglucose positron emission tomography/computed tomography (PET/
CT) as a surrogate of metabolism, fluorothymidine PET/CT as a surrogate of proliferation, and Cu-ATSM PET/CT as a
surrogate of hypoxia scans at different time points in a canine nasosinus model demonstrates: (1) a high degree of spatial
heterogeneity within tumors; (2) the complexity of the tumor response; and (3) our ability to monitor and potentially target
the spatiotemporal heterogeneity of tumors to maximize the therapeutic ratio in radiation therapy. Imaging has the potential to
both personalize treatments and inform the next generation of radiobiological models.
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the fractionation paradigm of radiation therapy? (19). We
are also becoming increasingly aware of the heterogeneity
of the biology within tumors. Should we integrate other
molecular or physiological signalsdmetabolism as
measured through fludeoxyglucose PET or proliferation as
measured through fluorothymidine PETdto pursue an
even more accurate description of the underlying biology?
(20). If we have an accurate description of the underlying
biology, how do we derive the corresponding dose
regimen and distribution? (21). Even the simple linkage
between an image of hypoxia and the resulting dose dis-
tribution requires maturation. It is also important that the
field consider the intrinsic uncertainties in the process of
radiation therapy delivery when defining its objectives and
design integrated solutions that are robust for clinical
application.
The intrinsically localized nature of radiation therapy
requires the field to be extremely attentive to sensitivity- and
specificity-related advances in cancer imaging. More spe-
cifically, technologies that are directly “adjacent” to our
current practice in terms of technology or care delivery can
have immediate effects. Two exciting technologies that
illustrate this point are highlighted in Figure 3 (22). First, thedevelopment of a highly specific form of prostate-specific
membrane antigen that has the potential to affect the care
of recurrent prostate cancer; and, second, the commercial
development of 7T MR imaging systems (23, 24). In the case
of novel prostate-specific membrane antigen agents, the
potential to monitor and target recurrent disease is as
important as the potential to use these agents to better
delineate focal disease in the prostate gland for localized
treatment. The potential effect of 7T imaging of the brain for
detection, decision to treat, and localization of primary and
metastatic lesions in the context of stereotactic radiosurgery
is likely but will require investment to characterize the
geometric accuracy at these field strengths.Image ValidationdNo More Pretty Pictures
The ingestion of new imaging signals into the radiation
therapy process is a significant challenge. Although the
field was aggressive in adopting CT imaging for definition,
delineation, and targeting, we have experienced sig-
nificantly slower uptake of other modalities, including MR
and molecular imaging. This is arguably in part owing to
the challenges the field has had in ensuring the geometric
MR 1.5T MR 7Tb
PET-DCFPyL PET-DCFPyL & CT
a
Fig. 3. (a) 18F-DCFPyL positron emission tomography (PET) and PET/computed tomography (CT) images from a patient
with biochemical recurrence after radical prostatectomy (prostate-specific antigen [PSA] 0.3 ng/dL at imaging). Subtle
increased radiotracer uptake can be seen in the right prostate bed (red arrowheads) compatible with local disease recurrence
(uptake in the urinary bladder is present anteromedial to the local recurrence). The patient subsequently underwent salvage
radiation therapy with a boost to the region of 18F-DCFPyL uptake, and the PSA level became undetectable. The lack of
radiotracer uptake outside the typical salvage pelvic radiation field increased the confidence level of the treating clinicians
that salvage radiation therapy was the appropriate course of action for this patient (22). (b) The effect of continued advances
in imaging performance on radiation therapy will directly alter patient care. This is illustrated in the comparison of magnetic
resonance images of a metastatic brain tumor of non-small cell lung carcinoma acquired at conventional (1.5T) and high-field
strength (7T). T2-weighted axial image from 1.5T brain magnetic resonance image “(A)” and T2-weighted axial image from
7.0T brain magnetic resonance image “(C)” in a patient with a metastatic brain tumor of non-small cell lung carcinoma (23).
(A color version of this figure is available at www.redjournal.org.)
Jaffray et al. International Journal of Radiation Oncology  Biology  Physics296and signal accuracy of these new signals and the expense
and availability of these modalities. In many ways, CT was
easy to adopt owing to its intrinsic geometric and radio-
metric precision (ie, Hounsfield units). MR imaging pro-
vides exquisite sensitivity but has lacked in specificity and
geometric integrity, thereby delaying its broad uptake in the
planning process. PET imaging, in contrast, provides
exquisite sensitivity and specificity but lacks broad avail-
ability of radiopharmaceuticals beyond fludeoxyglucose,
thereby generally limiting it to academic centers. The field
needs to invest in a more formal image ingestion process if
these new imaging signals are going to have the effect on
patient care that is possible (25). Such a formalization
would bring bright minds and industry partners to bear on
the current clinically validated problems. It would also
provide a “systems thinking” framework to balance thetradeoffs between greater accuracy in delineation against
greater precision in dose delivery.
Specific challenges that have been identified include (1)
the need for greater transparency in image-signal process-
ing to ensure quantitative performance of the imaging
system and quantitative consistency between imaging sys-
tems of the same modality used in a trial; (2) addressing the
problems of image distortion and registration; and (3)
pathology-based validation of the image-derived signals.
The development of the NIH’s Quantitative Imaging
Network is an excellent example of the broader commun-
ity’s awareness of the limiting nature these challenges have
on the field of cancer (26).
In addition to quantification, validation of the imaging sig-
nals must also be aggressively pursued. A founder of modern
medical education and practice, Sir William Osler stated it
Volume 101  Number 2  2018 Imaging advances and precision radiation oncology 297clearly “as is our pathology, so goes our practice”dclearly, we
must be cautious not to blindly “treat to the image.” Although
the number of reports on pathology-based validation is small
compared with those promoting a novel imaging technique,
an increase has occurred in the report of pathology-imaging
correlation studies enabled through 3-dimensional mapping
technologies (26, 27). The recent report byMenard et al (28)
on the correlation between multiparametricMR and biopsies
of the prostate gland highlights the scale of the problem,
because fused multiparametric MR imaging was inadequate
to delineate the tumor boundaries for focal salvage in 10 of 19
patients. Furthermore, the use of a 5-mm expansion margin
only reduced this cohort to 7 of 19 patients. This is exciting
work because it highlights the field’s growing capabilities
to quantify and validate image-based measurement of
diseaseda critical step toward image-enabled precision ra-
diation oncology.AutomationdManaging the 4 ‘V’s of Imaging
Data
The volume, variety, velocity, and veracity of imaging
data speak to the scale of the current and future challenges
to integrating imaging data into precision radiation
oncology. Managing the volume and variety requires
alternative approaches to traditional expert observer-based
analysis. Radiation oncology has been forced to be a
leader in the field of automated delineation to respond to
the power of inverse planning for intensity modulated
radiation therapy. The burden of delineating normal tis-
sues and target volumes has created a variety of algo-
rithms and software tools that are now in routine use in the
clinical setting (29). Similarly, automated methods are
being successfully applied to extract and validate features
that are beyond the quantification skills of the expert. This
is highlighted in the birth of the field of “radiomics.”
Although the extraction of phenotype data from images
is not novel, the extraction of features that are too subtle
in their intensity or their frequency of occurrence for
human experts to detect is now emerging as a predictive
biomarker of response (30, 31). Although the clinical ef-
fect of this work is intriguing, the technical effect of this
type of work needs to be recognized for its foreshadowing
of cancer medicine and science. The process involved in
radiomic analysis requires a massive scale-up in automa-
tion to manage the multitude of potentially relevant fea-
tures, the need to integrate segmentation data, the number
of image sets required to reach statistical significance, and
the processes for regression analysis and machine
learning. Further investments in automation will be
required to allow these tools to contribute to clinical de-
cision making, especially as time-dependent signatures
become part of the equation. It is likely that robust clinical
decision-making tools will need to integrate semantic,
algorithm-derived, and machine learningegenerated fea-
tures with more traditional clinical information formaximum patient benefit. As illustrated in Figure 1, the
volume, variety, and velocity of data flowing back from
the intervention to the decision-making process will
require automation. The veracity of the data refers to its
quality and affects the certainty with which the data can be
acted ondthis is of critical importance given the life and
death decisions being made in the design of a cancer pa-
tient’s treatment.
The adoption of automated “data mining” approaches
within the real-world setting of data-rich clinical care will
challenge the conventional paradigm of hypothesis-based
scientific research. Collecting and analyzing data for
patterns and correlations without a predefined mechanistic
or conceptual hypothesis has been enabled, and the field of
clinical science and the processes of regulatory approval
will need to wrestle with the incongruence with their
traditional approaches. This was a specific topic of dis-
cussion at the Workshop, and it was recognized that a large
amount of work must be done on both sides of the debate.Open SciencedBreaking Down the Silos
The American Society of Clinical Oncology proposed the
term “panomics” to describe the seemingly endless list of
measureable quantities of potential importance in the study
of cancer and the delivery of modern cancer care. The broad
scope of panomics speaks to not only the common interests
but also the common methods that the scientific and clinical
communities should be using to analyze the data sets found
in clinical and basic science of oncology. The creation of a
community of researchers that see their data as “features,”
regardless of their sourceddeep sequencing, 3-dimensional
CT imaging data, doseevolume histograms, or clinical
outcome datadis timely and powerful. Efforts by the
National Institutes of Health to create powerful archives are
ideal mechanisms to advance these efforts. The Cancer
Imaging Archive and The Cancer Genomics Archive are
linked with numerous site-specific research groups in
bladder, breast, glioma, head and neck, ovarian, and renal
cancers collaborating and reporting impactful research
findings (32). Paradoxically, although it is work led by
researchers in radiation oncology that are demonstrating the
value of these “panomic” approaches (33, 34), a need exists
for more radiation oncology data sets to be added to the
archive. The field of radiation oncology needs to engage
fully in the open science oncology community. Progress has
been made in this regard through the medical physics archive
on arXiv (available at: https://arxiv.org/list/physics.med-ph/
recent), where a variety of data sets are available for
further analysis. Although exciting, the amount of data is a
tiny fraction of the volume of well-curated imaging and
dosimetry data sets that sit within individual academic
radiation oncology programs. These need to be annotated
and drawn together with the corresponding pools of genomic
sequencing data in national archives to allow this research to
be more fruitful and more broadly effective.
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